Ver­tex deal for Scot­land — no deal for Eng­land

Cys­tic fi­bro­sis (CF) drug mak­er Ver­tex Phar­ma­ceu­ti­cals — which is still locked in ne­go­ti­a­tion with NHS Eng­land to en­dorse the use of its med­i­cines — has suc­cess­ful­ly ne­go­ti­at­ed a deal with Scot­tish au­thor­i­ties.

A month ago, the Scot­tish Med­i­cines Con­sor­tium spurned two of the com­pa­ny’s med­i­cines — Orkam­bi and Symke­vi — cit­ing un­cer­tain­ty over their long-term ef­fi­ca­cy in re­la­tion to their cost.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER